Lipoprotein (a) in calcific aortic valve disease: from genomics to novel drug target for aortic stenosis
Calcific aortic stenosis (AS) is the most common form of valve disease in the Western world and affects over 2.5 million individuals in North America. Despite the large burden of disease, there are no medical treatments to slow the development of AS, due at least in part to our incomplete understand...
Main Author: | George Thanassoulis |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2016-06-01
|
Series: | Journal of Lipid Research |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S0022227520351713 |
Similar Items
-
Current therapies for lowering lipoprotein (a)
by: Julian C. van Capelleveen, et al.
Published: (2016-09-01) -
Editor’s Pick: Lipoprotein(a) and Calcific Aortic Valve Stenosis
by: Constantine E. Kosmas, et al.
Published: (2019-10-01) -
Lipoprotein(a) as Orchestrator of Calcific Aortic Valve Stenosis
by: Johan G. Schnitzler, et al.
Published: (2019-11-01) -
Lipoprotein(a) and Its Autoantibodies in Association with Calcific Aortic Valve Stenosis
by: Anna L. Burdeynaya, et al.
Published: (2023-03-01) -
ANGPTL3 (Angiopoietin‐Like 3) Preferentially Resides on High‐Density Lipoprotein in the Human Circulation, Affecting Its Activity
by: Jordan M. Kraaijenhof, et al.
Published: (2023-11-01)